Trial · NCT03760445
Registered outcomes33
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 33 of 33
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Part 2 - all Expansion Cohorts: overall survival | first day of study treatment to 3 years after last patient is enrolled to Part 2 | determine overall survival by Expansion Cohort |
| Secondary | Part 2 - all Expansion Cohorts: event-free survival | first day of study treatment to 3 years after last patient is enrolled to Part 2 | determine event-free survival by Expansion Cohort |
| Secondary | Part 2 - all Expansion Cohorts: Percentage of subjects receiving Hematopoietic stem cell transplant (HSCT) | first day of study treatment to 3 years after last patient was enrolled to Part 2 | percentage of subjects receiving HSCT after study treatment by Expansion Cohort. |
| Secondary | Part 2 - Expansion Cohorts 1 to 3: disease-free survival (DFS) | first day of study treatment to 3 years after last patient enrolled to Part 2 | determine DFS by Expansion Cohort |
| Secondary | Part 2 - Expansion Cohorts 1 to 3: cumulative incidence of relapse (CIR) | first day of study treatment to 3 years after last patient enrolled to Part 2 | determine CIR by Expansion Cohort |
| Secondary | Part 2 - Expansion Cohorts 2 and 3 - proportion of subjects with CR/CRi with ABCR | first day of study treatment to 7.5 months after start of study treatment | proportion of subjects achieving CR or CRi with ABCR by Expansion Cohort |
| Secondary | Part 2 - Expansion Cohorts 1 and 2: proportion of subjects with minimal/measurable residual disease (MRD) negativity | first day of study treatment to 7.5 months after start of study treatment | proportion of subjects achieving MRD negativity by Expansion Cohort |
| Secondary | Part 2 - expansion cohort 2: midostaurin PK AUC | first day of study treatment to 7.5 month after start of study treatment | determine midostaurin AUC |
| Secondary | Part 2 - expansion cohort 2: midostaurin PK Cmax | first day of study treatment to 7.5 month after start of study treatment | determine midostaurin Cmax during induction and consolidation treatment |
| Secondary | Part 2 - expansion cohort 2: midostaurin PK Tmax | first day of study treatment to 7.5 month after start of study treatment | determine midostaurin Tmax during induction and consolidation treatment |
| Secondary | Part 1 - incidence of abnormal laboratory values | first day of study treatment to 8.5 months after start of study treatment | number of abnormal laboratory results by dose regimen for 1L AML and R/R AML subjects during study treatment + 30 days |
| Secondary | Part 1 - incidence of abnormal ECG results | first day of study treatment to 8.5 months after start of study treatment | number of abnormal ECG results by dose regimen for 1L AML and R/R AML subjects during study treatment + 30 days |
| Secondary | Part 1 - incidence of abnormal vital signs | first day of study treatment to 8.5 months after start of study treatment | number of abnormal vital signs by dose regimen for 1L AML and R/R AML subjects during study treatment + 30 days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03760445/registered?page=2